Literature DB >> 11172289

Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density.

S Nagura1, R Katoh, E Miyagi, M Shibuya, A Kawaoi.   

Abstract

To evaluate the relation between hypervascularization and vascular endothelial growth factor (VEGF) in the thyroid glands of patients with Graves disease, 19 Graves disease tissues and 6 normal thyroid tissues were studied by immunohistochemistry, in situ hybridization (ISH), and reverse transcriptase-polymerase chain reaction. The mean microvascular densities per follicle and per millimeter of the thyroid follicles' circumferential length in the Graves disease tissues (mean 3.37 and 13.91) were significantly higher than those in the normal thyroid tissues (mean 2.15 and 7.28) (tied P = .0005, P = .0185, and P < .05, respectively). An antibody against VEGF markedly reacted with hyperplastic follicular cells in Graves disease. The intensity was especially strong in the cells covering papillary growth regions containing accumulated microvessels. By ISH, VEGF messenger RNA (mRNA) signals were also detected in the hyperplastic follicular cells in Graves disease tissues and were especially strong in papillary growth regions. The VEGF receptor-1 (Flt-1) protein and mRNA were observed in endothelial cells of all Graves disease tissues. These findings suggest that hypervascularity in Graves disease tissues is related to upregulated VEGF expression in hyperplastic follicles.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172289     DOI: 10.1053/hupa.2001.21139

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  VEGF and GM-CSF levels in nodular thyroid diseases.

Authors:  Birsen Bilgici; Gulcin C Ecemis; Ozgur K Tuncel; Ilkay K Bayrak; Elif K Kan; Aysegul Atmaca
Journal:  Endocrine       Date:  2013-04-28       Impact factor: 3.633

2.  Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.

Authors:  Mattias K Andersson; Melker Göransson; Anita Olofsson; Carola Andersson; Pierre Aman
Journal:  BMC Cancer       Date:  2010-06-01       Impact factor: 4.430

3.  Vascular endothelial growth factor in thyroid cyst fluids.

Authors:  Andrea Hofmann; Alois Gessl; Friedrich Girschele; Clemens Novotny; Oskar Kienast; Anton Staudenherz; Robert Dudczak; Shuren Li
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

4.  The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.

Authors:  Joanna Klubo-Gwiezdzinska; Roman Junik; Ewa Kopczynska; Olga Juraniec; Hanna Kardymowicz
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

5.  Is rapid preparation for thyroidectomy in severe Graves' disease beneficial? The relationship between clinical and immunohistochemical aspects.

Authors:  Iyad Hassan; Radu Danila; Heisam Aljabri; Sebastian Hoffmann; Annette Wunderlich; Elias Karakas; Andreas Zielke
Journal:  Endocrine       Date:  2008-05-21       Impact factor: 3.633

6.  Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders.

Authors:  Asako Itoh; Katsumi Iwase; Shin Jimbo; Haruo Yamamoto; Naoki Yamamoto; Masahiro Kokubo; Takao Senda; Akira Nakai; Akio Nagagasaka; Takaaki Nagasaka; Yatsuka Hibi; Teppei Seko
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

7.  Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases.

Authors:  Ala'eddin Jebreel; James England; Karen Bedford; Justin Murphy; Laszlo Karsai; Stephen Atkin
Journal:  Int J Exp Pathol       Date:  2007-08       Impact factor: 1.925

8.  Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves' Disease.

Authors:  Shih-Ming Huang; Wei-Ting Liao; Chiou-Feng Lin; H Sunny Sun; Nan-Haw Chow
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

9.  Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.

Authors:  Marcello Mancini; Adelaide Greco; Giuliana Salvatore; Raffaele Liuzzi; Gennaro Di Maro; Emilia Vergara; Gennaro Chiappetta; Rosa Pasquinelli; Arturo Brunetti; Marco Salvatore
Journal:  BMC Med Imaging       Date:  2013-09-12       Impact factor: 1.930

Review 10.  Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors.

Authors:  Manuela Schmidinger
Journal:  EJC Suppl       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.